Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02077192 · ClinicalTrials.gov registry record · Phase 3
Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
A Phase 3 study of Immune Thrombocytopenic Purpura, sponsored by Rigel Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 123
- Enrollment target
- 20
- Study locations
NCT02077192 is a Phase 3 study of Immune Thrombocytopenic Purpura that has completed, run by Rigel Pharmaceuticals. The registered enrollment target is 123 participants, above the 95-participant average among 3 other Immune Thrombocytopenic Purpura trials with a reported enrollment target (29% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT02077192, a Phase 3 study of Immune Thrombocytopenic Purpura, has completed, sponsored by Rigel Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 123 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study was to assess the long term safety of fostamatinib in subjects with persistent/chronic ITP
Conditions Studied
Interventions
- DRUG Fostamatinib Disodium
Study Locations (20)
New South Wales
- Concord Repatriation General Hospital - Concord
- Liverpool Hospital - Liverpool
- Prince of Wales Hospital - Randwick
- Westmead Hospital - Westmead
Other
- Hanusch-Krankenhaus Wiener Gebietskrankenkasse - Vienna
- UMHAT Dr. Georgi Stranski, EAD, Pleven, Clinic of Hematology - Pleven
- UMHAT Aleksandrovska, EAD - Sofia
New York
- Weill Cornell Medical College/New York Presbyterian Hospital - New York
- Weill Cornell Medicine - New York
North Carolina
- East Carolina University, Brody School of Medicine - Greenville
- W.G. "Bill" Hefner VA Medical Center - Salisbury
Arizona
- Arizona Oncology Associates - Tucson
Illinois
- Bleeding & Clotting Disorders Institute - Peoria
Indiana
- Horizon Oncology Research, Inc - Lafayette
Maryland
- Center for Cancer and Blood Disorders - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2014-10 |
| Est. Completion | 2020-06-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02077192
The ClinicalTrials.gov registry entry for NCT02077192 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 95-participant average among 3 other Immune Thrombocytopenic Purpura trials with a reported enrollment target (29% higher). The listed sponsor is Rigel Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Immune Thrombocytopenic Purpura appearing as the primary indexed condition, and to 1 intervention - of which Fostamatinib Disodium is the first listed.
NCT02077192 reports 20 study locations spanning 13 distinct geographic areas - top geographies include New South Wales, Other, New York.
Frequently Asked Questions
What is clinical trial NCT02077192 about?
NCT02077192 is a clinical study titled "Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)". The primary objective of this study was to assess the long term safety of fostamatinib in subjects with persistent/chronic ITP
What is the current status of trial NCT02077192?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 123 participants. The study started on 2014-10. Estimated completion is 2020-06-02.
What conditions does trial NCT02077192 study?
This clinical trial studies the following conditions: Immune Thrombocytopenic Purpura.
What interventions are being tested in trial NCT02077192?
The interventions under investigation include: Fostamatinib Disodium (DRUG).
Who is sponsoring clinical trial NCT02077192?
This trial is sponsored by Rigel Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02077192 being conducted?
This trial has 20 study locations across Arizona, Illinois, Indiana, Maryland, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immune Thrombocytopenic Purpura
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
COMPLETED · Phase 3
-
Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura
COMPLETED · NA
-
An Epidemiological Study of Subjects With Immune Thrombocytopenic Purpura to Evaluate the Relationship Between Platelet Counts, Endogenous Thrombopoietin Levels, Endogenous Anti-Thrombopoietin Antibodies, and Selected Autoimmune Markers
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.